Mutational analysis of tyrosine kinase domain of BCR-ABL1 gene in chronic myeloid leukemia patients resistant to tyrosine kinase inhibitors

被引：0
|
作者：
Kihel, I. [3 ]
Nachi, M. [2 ]
Cayuela, J. [3 ]
Bekadja, M. A. [1 ]
Note, A. [3 ]
机构：
[1] Fac Med Ahmed Ben Bella, Oran, France
[2] EHS BURN ORAN, Fac Med Ahmed Ben Bella, Med Biochem & Mol Biol Res Lab, Oran, France
[3] St Louis Hosp, Mol Lab, Paris, France
来源：
CLINICA CHIMICA ACTA | 2024年 / 558卷
关键词：
D O I：
10.1016/j.cca.2024.119279
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia
    Schiffer, Charles A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (03): : 258 - 265
  • [42] Optimal Time Points for BCR-ABL1 Tyrosine Kinase Domain Mutation Analysis on the Basis of European LeukemiaNet Recommendations in Chronic Myeloid Leukemia
    Yoo, Hea-Lyun
    Kim, Soo-Hyun
    Choi, Soo-Young
    Lee, Sung-Eun
    Kim, Dong-Wook
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (07): : 406 - +
  • [43] Heterocyclic Compounds as Bcr-Abl Tyrosine Kinase Inhibitors Against Chronic Myeloid Leukemia
    Gado, Sarah
    Hassan, Mohammed Al-Kassim
    Kisla, Mehmet Murat
    Ates-Alagoz, Zeynep
    MEDICINAL CHEMISTRY, 2024,
  • [44] Reflexive Screening for BCR-ABL1 Kinase Domain Mutations in Chronic Myeloid Leukemia
    Langabeer, Stephen E.
    McCarron, Sarah L.
    Haslam, Karl
    Preston, Lisa
    CLINICAL LABORATORY, 2016, 62 (05) : 975 - 976
  • [45] Stem Cell Transplantation for Patients With Chronic Myeloid Leukemia Resistant to Tyrosine Kinase Inhibitors With BCR-ABL Kinase Domain Mutation T315I
    Velev, Nikolai
    Cortes, Jorge
    Champlin, Richard
    Jones, Dan
    Rondon, Gabriela
    Giralt, Sergio
    Borthakur, Gautam
    Kantarjian, Hagop M.
    De Lima, Marcos
    CANCER, 2010, 116 (15) : 3631 - 3637
  • [46] Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors
    Cortes, Jorge
    Jabbour, Elias
    Kantarjian, Hagop
    Yin, C. Cameron
    Shan, Jianqin
    O'Brien, Susan
    Garcia-Manero, Guillermo
    Giles, Francis
    Breeden, Megan
    Reeves, Nubia
    Wierda, William G.
    Jones, Dan
    BLOOD, 2007, 110 (12) : 4005 - 4011
  • [47] Economic Burden of Adverse Events Among Patients with Chronic Myelogenous Leukemia Treated with BCR-ABL1 Tyrosine Kinase Inhibitors
    Lin, Jay
    Dinara, Makenbaeva
    Robyn, Bilmes
    Lingohr-Smith, Melissa
    Wallis, Nicola
    BLOOD, 2015, 126 (23)
  • [48] Assessment of BCR-ABL1 transcript levels at 3 months is the major determinant for outcome in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
    Katalinic, D.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S100 - S100
  • [49] Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
    Goldman, JM
    Melo, JV
    NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14): : 1084 - 1086
  • [50] Analysis of BCR–ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype
    H Grant
    X Jiang
    J Stebbing
    L Foroni
    C Craddock
    M Griffiths
    R E Clark
    S O'Brien
    J S Khorashad
    G Gerrard
    L Wang
    J A E Irving
    M Wang
    L Karran
    M J S Dyer
    D Forrest
    K Page
    C J Eaves
    A Woolfson
    Leukemia, 2010, 24 : 1817 - 1821
12345